Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 13900

1.

Clinical Course and Management of Hypertrophic Cardiomyopathy.

Pascoe SJ.

N Engl J Med. 2018 Nov 15;379(20):1976-7. doi: 10.1056/NEJMc1812159. No abstract available.

PMID:
30440115
2.

Clinical Course and Management of Hypertrophic Cardiomyopathy.

Bachmayer K.

N Engl J Med. 2018 Nov 15;379(20):1976. doi: 10.1056/NEJMc1812159. No abstract available.

PMID:
30440114
3.

Clinical Course and Management of Hypertrophic Cardiomyopathy.

Maron BJ.

N Engl J Med. 2018 Nov 15;379(20):1977. doi: 10.1056/NEJMc1812159. No abstract available.

PMID:
30428294
4.

Layer-specific strain analysis of left ventricular myocardium after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Zhang J, Zhu L, Jiang X, Hu Z.

Medicine (Baltimore). 2018 Nov;97(45):e13083. doi: 10.1097/MD.0000000000013083.

5.

Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.

Lowey S, Bretton V, Joel PB, Trybus KM, Gulick J, Robbins J, Kalganov A, Cornachione AS, Rassier DE.

Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):11238-11243. doi: 10.1073/pnas.1802967115. Epub 2018 Oct 15.

PMID:
30322937
6.

The Effects of Dracocephalum Heterophyllum Benth Flavonoid on Hypertrophic Cardiomyocytes Induced by Angiotensin II in Rats.

Jiang H, Zhang C, He W.

Med Sci Monit. 2018 Sep 10;24:6322-6330. doi: 10.12659/MSM.908912.

7.

Analytical validation of platelet microparticle quantification in cats.

Cremer SE, Koch J, Graversen N, Gravgaard AS, Langhorn R, Kristensen AT, Willesen JL, Nielsen LN.

Vet Clin Pathol. 2018 Sep;47(3):386-395. doi: 10.1111/vcp.12641.

PMID:
30199121
8.

Prognostic Impact of Left Atrial Minimal Volume on Clinical Outcome in Patients with Non-Obstructive Hypertrophic Cardiomyopathy.

Shin SH, Jang JH, Baek YS, Kwon SW, Park SD, Woo SI, Kim DH, Kwan J.

Int Heart J. 2018 Sep 26;59(5):991-995. doi: 10.1536/ihj.17-606. Epub 2018 Aug 29.

9.

Telomere shortening is a hallmark of genetic cardiomyopathies.

Chang ACY, Chang ACH, Kirillova A, Sasagawa K, Su W, Weber G, Lin J, Termglinchan V, Karakikes I, Seeger T, Dainis AM, Hinson JT, Seidman J, Seidman CE, Day JW, Ashley E, Wu JC, Blau HM.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9276-9281. doi: 10.1073/pnas.1714538115. Epub 2018 Aug 27.

10.

Clinical and echocardiographic parameters as risk factors for atrial fibrillation in patients with hypertrophic cardiomyopathy.

Klopotowski M, Kwapiszewska A, Kukula K, Jamiolkowski J, Dabrowski M, Derejko P, Oreziak A, Baranowski R, Spiewak M, Marczak M, Klisiewicz A, Szepietowska B, Chmielak Z, Witkowski A.

Clin Cardiol. 2018 Oct;41(10):1336-1340. doi: 10.1002/clc.23050. Epub 2018 Oct 16.

11.

Clinical Course and Management of Hypertrophic Cardiomyopathy.

Maron BJ.

N Engl J Med. 2018 Aug 16;379(7):655-668. doi: 10.1056/NEJMra1710575. Review. No abstract available.

PMID:
30110588
12.

Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.

Sakai T, Naito AT, Kuramoto Y, Ito M, Okada K, Higo T, Nakagawa A, Shibamoto M, Yamaguchi T, Sumida T, Nomura S, Umezawa A, Miyagawa S, Sawa Y, Morita H, Lee JK, Shiojima I, Sakata Y, Komuro I.

Int Heart J. 2018 Sep 26;59(5):1096-1105. doi: 10.1536/ihj.17-730. Epub 2018 Aug 11.

13.

What is the role of apical ventriculotomy in children and young adults with hypertrophic cardiomyopathy?

Thompson AJ, Dearani JA, Johnson JN, Schaff HV, Towe EC, Palfreeman J, Wackel PL, Cetta F.

Congenit Heart Dis. 2018 Jul;13(4):617-623. doi: 10.1111/chd.12618. Epub 2018 Jul 17.

PMID:
30019505
14.

Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin.

Rohde JA, Roopnarine O, Thomas DD, Muretta JM.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7486-E7494. doi: 10.1073/pnas.1720342115. Epub 2018 Jul 17.

PMID:
30018063
15.

First identification of homozygous truncating CSRP3 variants in two unrelated cases with hypertrophic cardiomyopathy.

Janin A, Bessière F, Chauveau S, Chevalier P, Millat G.

Gene. 2018 Nov 15;676:110-116. doi: 10.1016/j.gene.2018.07.036. Epub 2018 Jul 17.

PMID:
30012424
16.

Hypertrophic obstructive cardiomyopathy with anomalous left circumflex coronary artery.

Woźnica A, Tyczyński P, Brzozowski P, Skowroński J, Różański J, Witkowski A.

Kardiol Pol. 2018;76(7):1118. doi: 10.5603/KP.2018.0141. No abstract available.

17.

Investigation of myocardial dysfunction using three-dimensional speckle tracking echocardiography in a genetic positive hypertrophic cardiomyopathy Chinese family.

Wang J, Guo RQ, Guo JY, Zuo L, Lei CH, Shao H, Wang LF, Zhang YM, Liu LW.

Cardiol Young. 2018 Sep;28(9):1106-1114. doi: 10.1017/S1047951118000860. Epub 2018 Jul 6.

PMID:
29978770
18.

[Roles of Sodium-Glucose Cotransporter 1 (SGLT1) in the Induction of Cardiac Remodeling].

Hirose M, Matsushita N, Ishida N, Ibi M, Saito M.

Yakugaku Zasshi. 2018;138(7):939-943. doi: 10.1248/yakushi.17-00223-2. Review. Japanese.

19.

Phenotype-modifying Factors in Hypertrophic Cardiomyopathy. Response.

Pérez-Sánchez I, Sabater-Molina M, Muñoz-Esparza C, Gimeno-Blanes JR.

Rev Esp Cardiol (Engl Ed). 2018 Sep;71(9):770-771. doi: 10.1016/j.rec.2018.04.023. Epub 2018 Jun 25. English, Spanish. No abstract available.

PMID:
29954718
20.

The vital role of exercise testing in hypertrophic cardiomyopathy.

Coats CJ.

Int J Cardiol. 2018 Nov 15;271:200-201. doi: 10.1016/j.ijcard.2018.06.028. Epub 2018 Jun 7. No abstract available.

PMID:
29921517

Supplemental Content

Loading ...
Support Center